At 9.2% CAGR, Middle East & Africa Heart Transplant Market is Projected to be Worth US$ 432.74 Million by 2030, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa heart transplant market was valued at US$ 213.52 million in 2022 and is expected to reach US$ 432.74 million by 2030, registering a CAGR of 9.2% from 2022 to 2030. Use of AI in transplantation procedures and growing geriatric population are among the critical factors attributed to the Middle East & Africa heart transplant market expansion.

A uniquely designed system backed by artificial intelligence (AI) facilitates the detection of early signs and seriousness of the host rejection post-heart transplantation. The endomyocardial biopsy (EMB) screening signifies the standard of care for identifying allograft rejections after a heart transplant. In 2022, a new AI system was designed known as the Cardiac Rejection Assessment Neural Estimator (CRANE), which can be used in tandem with medical assessments for rapid and precise diagnosis. CRANE also helps reduce differences regarding the presence and severity of heart rejection in the host body. It is a deep?learning-based AI system for the automated assessment of gigapixel whole-slide images obtained from EMBs. In 2020, the National Institute of Health granted US$ 3.2 million to studies based on the exploration of the capabilities of AI in heart transplants. With this grant, researchers from Perelman School of Medicine (the University of Pennsylvania), Case Western Reserve University, Cleveland Clinic, and Cedars-Sinai Medical Center aimed to study what causes the rejection of a new heart and how to manage it. They used AI to analyze cardiac biopsy tissue images, finding the types of immune cells that play an instrumental role in new heart rejection. Thus, the adoption of AI in heart transplantation procedures is likely to bring new trends in the market in the coming years.

On the contrary, high cost of surgeries hampers the Middle East & Africa heart transplant market.

Based on surgery type, the Middle East & Africa heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart segment held 79.0% share of Middle East & Africa heart transplant market in 2022, amassing US$ 168.69 million. It is projected to garner US$ 347.24 million by 2030 to expand at 9.4% CAGR during 2022-2030.

In terms of type, the Middle East & Africa heart transplant market is bifurcated into donor live heart and artificial heart. The donor live heart segment held 74.1% share of Middle East & Africa heart transplant market in 2022, amassing US$ 158.29 million. It is projected to garner US$ 315.44 million by 2030 to expand at 9.0% CAGR during 2022-2030. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.

Based on end user, the Middle East & Africa heart transplant market is segmented into hospitals, cardiac centers, and others. The hospitals segment held 59.2% share of Middle East & Africa heart transplant market in 2022, amassing US$ 126.44 million. It is projected to garner US$ 262.18 million by 2030 to expand at 9.5% CAGR during 2022-2030.

By country, the Middle East & Africa heart transplant market has been categorized into Saudi Arabia, South Africa, the UAE, and Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 39.9% share of Middle East & Africa heart transplant market in 2022. It was assessed at US$ 85.15 million in 2022 and is likely to hit US$ 178.12 million by 2030, exhibiting a CAGR of 9.7% during 2022-2030.

Key players operating in the Middle East & Africa heart transplant market are Terumo Corp, Abbott Laboratories, SynCardia Systems LLC, and LivaNova Plc, among others.

• In June 2021, Abbott Laboratories announced that it has enhanced its capacity and supply for mechanical circulatory support (MCS) devices, Medtronic HeartWare ventricular assist device (HVAD). In addition, the company announced providing support training and education programs for its HeartMate 3 heart pump.
  
  
• In January 2020, Abbott Laboratories announced that the Food and Drug Administration (FDA) approved its HeartMate 3 left ventricular assist device (LVAD). LVAD is a minimally invasive surgical technique for the placement that avoids open surgery. In 2017, the FDA approved HeartMate 3 for bridge therapy for patients awaiting a heart transplant.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com